Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-06-08
2011-11-22
Singh, Anoop (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S278100
Reexamination Certificate
active
08063022
ABSTRACT:
The invention provides a method of preventing the formation of inhibitory antibodies in a mammal undergoing gene therapy. The method comprises administering to the mammal an immunosuppressive agent in conjunction with the gene therapy.
REFERENCES:
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5952221 (1999-09-01), Kurtzman et al.
patent: 6071883 (2000-06-01), Chen et al.
patent: 6093392 (2000-07-01), High et al.
patent: 6093567 (2000-07-01), Gregory et al.
patent: 6251957 (2001-06-01), Wilson et al.
patent: 6929796 (2005-08-01), Conti-Fine
patent: 2003/0004091 (2003-01-01), Perricaudet et al.
patent: 2003/0130221 (2003-07-01), High et al.
patent: 2003/0134815 (2003-07-01), Crystal
patent: WO 96/25177 (1996-08-01), None
patent: WO 97/39776 (1997-10-01), None
Potter et al., Review- The use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product,1999, Ann. NY Acad. Sci., vol. 875, pp. 159-174.
Verma et al, Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.
Anderson, Human gene therapy, 1998, Nature, vol. 392, pp. 25-30.
Smith et al., Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vevtor, 1996, Gene Therapy, vol. 3, pp. 496-502.
Kay et al., Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, 2000, Nature Genetics, vol. 24, pp. 257-261.
Jooss et al., Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung, 1996, Human Gene Therapy, vol. 7, pp. 1555-1566.
Fang et al., Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression, 1995, Human Gene Therapy, vol. 6, pp. 1039-1044.
Rubanyi, The future of human gene therapy, 20001, Molecular Aspects of Medicine, vol. 22, pp. 113-142.
RW Herzog et al., Molecular Therapy, “Muscle-Directed Gene Transfer and Transient Immune Suppression Result in . . . Hemophilia B Caused by a Null Mutation,” Sep. 2001, vol. 4, No. 3, pp. 192-200.
Warrier et al., Blood Caput Fibrinolysis Mar. 1998: 9 Suppl 1: S125-8.
Nilsson, PNAS, 83:9169-9173, 1986.
Herzog et al., Blood 1997, vol. 90, No. 10, Part 1, Suppl [1], pp. 1057-1057.
Tripathy, Nat. Med. 1996, vol. 2, pp. 545-550.
Chirmule et al. Gene Therapy, 6, pp. 1574-1583, 1999.
Xiao et al. Molecular Therapy, 1, pp. 323-329, 2000.
Arruda et al Blood. May 1, 2005;105(9):3458-64).
Ecke, Goodman & Gilman's The Pharmacological basis of Therapeutics, 1996, McGraw-Hill, New York, NY. pp. 77-101.
Arruda et al Blood, 2004, 103(1) 85-92.
Manno et al Nature Medicine, 2006, 12(3), 342-347.
Gautam et al Am J Respir Med, 2002;1(1):35-46.
Ponder et al Current Opinion Hematol, 2006, 13, 301-307.
Kaiser Science, 317, 2007, 580.
Chao et al The Mount Sinai J of Medicine, 71(5), 2004, 305-312.
Walsh Gene Therapy, 2003, 10, 999-1003 .
Herzog et al, Human Gene therapy, 13:1281-1291 2002.
Matthew et al Journal of Clinical Investigation, 1987, 79, 746-753.
Cater, 1992, “Adeno-associated Virus Vectors,” Biotechnology, 3: 533-539.
Dai, et al., 1995 “Cellular and Humoral Immune Responses to Adenoviral Vectors Containing Factor IX Gene: Tolerization of Factor IX and Vector Antigens Allows for Long-term Expression,” Proc. Natl. Acad. Sci. USA, 92:1401-1405.
High, et al., 1995, “Factor IX In: Molecular Basis of Thrombosis and Hemostasis,” High and Roberts, (eds.), Marcel Dekker, Inc.
Herzog, et al., 1997, “Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX After Intramusular Injection of Recombinant Adeno-associated Virus,” Proc. Natl. Acad. Sci. USA, 94:5804-5809.
Herzog, et al., 1999, “Long-term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated by Adeno-associated Viral Vector,”Nature Medicine, 5:56-63.
Herzog and High, 1999, “Adeno-associated Vrius-mediated Gene Transfer of Factor IX for Treatment of Hemophilia B by Gene Therapy,” In: Thrombosis and Hemostasis, 1999 State of the Art, Hoyer L(ed.), 82:540-546.
Kaplitt, et al., 1994, Long-term Gene Expression and Phenotypic Correction Using Adeno-associated Virus Vectors in the Mammalian Brain, Nature Genetics, 8:148-154.
Kay, et al., 1993, “In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs,” Science, 262:117-119.
Kay, et al., 1997,“Transient Immunomodulation with Anti-CD40 Ligand Antibody and CTLA41g Enhances Persistence and Secondary Adenovirus-mediated Gene Transfer Into Mouse Liver,” Proc. Natl. Acad. Sci. USA, 94:4686-4691.
Kessler, et al., “Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein,” Proc. Natl. Acad. Sci. USA, 93: 14082-14087.
Matsushita, et al., 1998, “Adeno-associated Virus Vectors can be Efficiently Produced without Helper Virus,” Gene Therapy, 5:938-945.
Matsushita, et al.,1999, Proceedings of the 2ndAnnual American Society of Gene Theraphy, Washington, DC, Jun. 9-13, p. 2a.
Nakai, et al., 1998, “Adeno-associated Viral Vector-mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver,” Blood, 91: 4600-4607.
Skulimowski, et al., 1995, “Adeno-associated Virus: Integrating Vectors for Human Gene Therapy,” Methods in Molecular Genetics 7:7-12.
Tripathy, et al., 1996, “Immune Responses to Transgene-encoded Proteins Limit the Stability of Gene Expression after Injection of Replication-defective Adenovirus Vectors,” Nature Medicine, 2:545-550.
Tripathy, et al., 1996, “Long -term Expression of Erythropoietin in the Systemic Circluation of Mice after Intramuscular Injection of a Plasmid DNA Vector,” Proc. Natl. Acad. Sci. USA, 93:10876-10880.
Xiao, et al., Efficient Long-term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-associated Virus Vector, Journal of Virology, 70:8098-8108.
Yang, et al., 1996 “Immunology of Gene Therapy with Adenoviral Vectors in Mouse Skeletal Muscle,” Human Molecular Genetics, 5:1703-1712.
Herzog, R.W., et al., Long-Term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated by Adeno-Associated Viral Vector, Nature Medicine, 5(1):56-63 (1999).
Snyder, R. O., Correction of Hemophilia B in Canine and Murine Models Using Recombinant Adeno-Associated Viral Vectors, Nature Medicine, 5(1):64-70 (1999).
Arruda Valder R.
Fields Paul A.
Herzog Roland W.
High Katherine A.
Dann Dorfman Herrell & Skillman
Rigaut Kathleen D.
Singh Anoop
The Children's Hospital of Philadelphia
LandOfFree
Methods for preventing formation of inhibitory antibodies in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing formation of inhibitory antibodies in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing formation of inhibitory antibodies in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307388